 |
|
Glaucoma surgery in the blink of an eye
September 12, 2007TEL AVIV - Prof. Ehud Assia, of Tel Aviv University's Sackler School of Medicine is, quite simply, a rock star in the field of eye surgery.
One of a small number of surgeons in the world who currently perform a complicated form of glaucoma surgery, Prof. Assia has developed a novel laser device that promises to revolutionize treatment of the disease. The laser, called the OTS134 for now, is expected to give most practicing eye surgeons the ability to master complex glaucoma surgery very quickly.
Glaucoma, nicknamed the silent sight thief, is the second leading cause of blindness in the West. "Glaucoma is a serious problem that starts to cause nerve damage to people without them realizing that anything is happening to their eyesight, often before it is too late, " says Prof. Assia, who is also the director of Ophthalmology at Meir Hospital in Israel, which treats thousands of glaucoma patients each year.
The most common surgical treatment in use today perforates the wall of the eye, often resulting in collapse of the eyeball, infection, cataract formation and other complications. A more effective and elegant approach, a specialty of Prof. Assia's, involves penetration of the eye wall to a depth of only about 95 percent, leaving a razor-thin layer intact. The difference between success and failure may amount to just a few microns.
This highly-specialized non-penetrating surgery, requiring years of rigorous training and great skill, is performed by only a small number of surgeons at leading international ophthalmology centers. But a small observation led Prof. Assia to think about a method that could make the procedure accessible to eye surgeons without the long and involved training.
"Several years ago I served as a consultant for a company that produces CO2 lasers, which are used for different kinds of cosmetic and skin surgery. Because it is a relatively strong type of laser, it was not a likely candidate for use on something as delicate as the eye. However, one of the CO2 laser's unique characteristics is that it does not function when it comes in contact with liquid. It occurred to me that this would be a perfect fit for non-penetrating surgery, because the moment the CO2 laser came in contact with the intra-ocular liquid, it would automatically shut off," he recalls.
Working in partnership with the Israeli-based company IOPtima, Prof. Assia has already carried out a series of successful human trials. A larger worldwide study will take place this year before the company launches the OTS134 - as it plans to do in the United States - by the middle of 2008.
Glaucoma affects 3 million Americans every year, with onset around the age of 40. It is a disease that is brought on by a seemingly harmless increase of pressure in the eyeball. When this pressure builds up over time, the aging body cannot seem to correct the pressure effectively. Glaucoma eventually damages the optical nerve in the eye, with extreme tunnel vision and complete blindness ensuing.
"There are drug treatments that can reduce the intra-ocular pressure, but that means life-long treatment involving two or three kinds of eye drops three times a day," says Prof. Assia. "We find that a large number of patients don't comply with this treatment, especially because the harmful effects of not taking the medicine properly are not immediately felt."
Although he counsels that surgical approaches to glaucoma also carry risks, the OTS134 is a promising tool for more widespread treatment with fewer complications.
American Friends of Tel Aviv University
The most common surgical treatment in use today perforates the wall of the eye, often resulting in collapse of the eyeball, infection, cataract formation and other complications. A more effective and elegant approach, a specialty of Prof. Assia's, involves penetration of the eye wall to a depth of only about 95 percent, leaving a razor-thin layer intact. The difference between success and failure may amount to just a few microns.
This highly-specialized non-penetrating surgery, requiring years of rigorous training and great skill, is performed by only a small number of surgeons at leading international ophthalmology centers. But a small observation led Prof. Assia to think about a method that could make the procedure accessible to eye surgeons without the long and involved training.
"Several years ago I served as a consultant for a company that produces CO2 lasers, which are used for different kinds of cosmetic and skin surgery. Because it is a relatively strong type of laser, it was not a likely candidate for use on something as delicate as the eye. However, one of the CO2 laser's unique characteristics is that it does not function when it comes in contact with liquid. It occurred to me that this would be a perfect fit for non-penetrating surgery, because the moment the CO2 laser came in contact with the intra-ocular liquid, it would automatically shut off," he recalls.
Working in partnership with the Israeli-based company IOPtima, Prof. Assia has already carried out a series of successful human trials. A larger worldwide study will take place this year before the company launches the OTS134 - as it plans to do in the United States - by the middle of 2008.
Glaucoma affects 3 million Americans every year, with onset around the age of 40. It is a disease that is brought on by a seemingly harmless increase of pressure in the eyeball. When this pressure builds up over time, the aging body cannot seem to correct the pressure effectively. Glaucoma eventually damages the optical nerve in the eye, with extreme tunnel vision and complete blindness ensuing.
"There are drug treatments that can reduce the intra-ocular pressure, but that means life-long treatment involving two or three kinds of eye drops three times a day," says Prof. Assia. "We find that a large number of patients don't comply with this treatment, especially because the harmful effects of not taking the medicine properly are not immediately felt."
Although he counsels that surgical approaches to glaucoma also carry risks, the OTS134 is a promising tool for more widespread treatment with fewer complications.
American Friends of Tel Aviv University
Glaucoma Current Events and Glaucoma News RSSMelatonin may save eyesight in inflammatory disease
Current research suggests that melatonin therapy may help treat uveitis, a common inflammatory eye disease. The related report by Sande et al., "Therapeutic Effect of Melatonin in Experimental Uveitis," appears in the December issue of The American Journal of Pathology.
Eye conditions linked with obstructive sleep apnea
If a good night's sleep helps the brain and body perform better, it's a good guess that sleep problems can cause more than just fatigue. Numerous studies have shown a connection between sleep disorders and medical conditions such as cardiovascular disease, cerebrovascular disease, and metabolic disorders, including the risk of obesity and diabetes mellitus. In the November issue of Mayo Clinic Proceedings, Mayo Clinic researchers outline several interesting associations between sleep disorders and eye disease.
Vision loss more common in people with diabetes
Visual impairment appears to be more common in people with diabetes than in those without the disease, according to a report in the October issue of Archives of Ophthalmology, one of the JAMA/Archives journals.
Medication slows progression of myopia in children
Daily treatment with a medication called pirenzepine can slow the rate of progressive myopia, or nearsightedness, in children, reports a study in the August issue of the Journal of AAPOS (American Association for Pediatric Ophthalmology and Strabismus).
Glaucoma procedure now available at Mayo Clinic aims to prevent further eye damage
For the first time in Florida, patients with glaucoma have a new treatment option known as the Trabectome.
Case Western Reserve and Penn State investigators inhibit corneal inflammation
Researchers from the Case Western Reserve University School of Medicine and Penn State Hershey College of Medicine identified a novel therapeutic that reduces sterile inflammation within the cornea.
Glaucoma report points to increased costs
A new Centre for Eye Research Australia/ Access Economics report shows the cost of glaucoma will more than double in the next two decades.
'Fluorescent' cells give early warning for eye disease
Scientists at the University of Michigan have shown that their new metabolic imaging instrument can accurately detect eye disease at a very early stage.
Role identified for glaucoma gene and related signaling pathway
Researchers have found that a gene and a related signaling pathway play a role in the development of glaucoma, which is a common cause of visual impairment and blindness worldwide.
Cost of glaucoma medications may impact treatment
In the United States, the management of glaucoma costs about $2.5 billion per year. Of the $1.9 billion in direct costs, glaucoma medications account for an estimated 38% to 52% of the total.
More Glaucoma Current Events and Glaucoma News Articles
 | What Your Doctor May Not Tell You About(TM) Glaucoma: The Essential Treatments and Advances That Could Save Your Sight (What Your Doctor May Not Tell You About...) by Gregory K. Harmon, Nancy Intrator Most people can recite the warning signs of cancer and just about everybody knows the risk factors for heart disease. But how many people know the facts about glaucoma? Well, what you don't know might save your sight. Glaucoma is an insidious and painful disease that is often misunderstood, and ultimately can rob patients of their sight completely. Between three and four million Americans are... |
 | Shields' Textbook of Glaucoma This popular reference on glaucoma management now offers a more practical and clinically focused textbook for ophthalmologists and residents. Readers find new or extensively updated information on cellular and molecular biology of the eye, molecular genetics and classification of glaucomas, epidemiology and public health, screening and risk assessment, congenital and developmental glaucomas with... |
 | Get It Up! Revealing the Simple Surprising Lifestyle that Causes Migraines, Alzheimer's, Stroke, Glaucoma, Sleep Apnea, Impotence,...and More! by Sydney Ross Singer, Soma Grismaijer Imagine curing migraines by merely altering a simple lifestyle habit. Even more, imagine this same lifestyle habit, something we take for granted as normal, can also cause Alzheimer's disease, impotence, stroke, glaucoma, sleep apnea, and more. There would finally be hope, real hope, for the countless millions who suffer from these conditions, and for their families and loved ones who... |
 | Glaucoma (Essentials in Ophthalmology) This third Glaucoma volume of the Essentials in Ophthalmology series, as in the first and the second, provides a picture of recent progress in the field of glaucoma, in both basic clinical research and applied clinical science. Its intention is not to replace textbooks on glaucoma, but to serve as a conceptual bridge between original research and textbook presentation. Topics include: ... |
 | The Pediatric Glaucomas by Anil Mandal, Peter Netland Here is a comprehensive and up-to-date source on the origins, diagnosis, and management of glaucomas in children. The authors balance evidence-based management guidelines with perspectives from their abundant direct clinical experience. Coverage includes the most recent advances in genetics, medical therapy, and surgical treatment…long-term management…treatment of intractable glaucomas…and... |
 | Surgical Techniques in Ophthalmology Series: Glaucoma Surgery: Text with DVD by Teresa C. Chen Whether you're in training or an established practitioner, the brand-new Surgical Techniques in Ophthalmology Series features the essential information you need on a variety of surgical maneuvers in six subspecialty areas. Every author has been carefully selected for each title based on their experience and wealth of clinical expertise. And, each book is presented in a concise, templated format... |
 | Glaucoma: Color Atlas & Synopsis of Clinical Ophtalmology (Wills Eye Series) by Douglas J. Rhee, Christopher J. Rapuano Quick reference and color atlases covering 5 sub-specialties in ophthalmology. Each book will cover the following areas: Epidemiology and Etiology; History Physical Examination; Differential Diagnosis;Laboratory and Special Examinations; Diagnosis; Prognosis;... |
 | Coping With Glaucoma by Edith Marks, Rita Mountauredes |
 | GLAUCOMA: AN OPEN-WINDOW TO NEURODEGENERATION AND NEUROPROTECTION, Volume 173 (Progress in Brain Research) Glaucoma is one of the main causes of blindness throughout the world. It is characterized by death of the retinal ganglion cells, which is associated with loss of the axons making up the optic nerve. Recent studies have demonstrated support for the classification of glaucoma as a degenerative disease of the central nervous system (CNS). The search for treatment modalities that are effective for... |
 | Mechanisms of the Glaucomas: Disease Processes and Therapeutic Modalities The mechanisms of the various forms of glaucoma were unknown at the outset of the twentieth century. Late in the twentieth century, two nascent areas of research were beginning to provide glimpses of what the twenty-first century held in store for the future of glaucoma: the mechanisms of glaucomatous optic neuropathy and the molecular basis of the glaucomas. In Mechanisms of the Glaucomas:... |
| © 2009 BrightSurf.com |